+3.17% for Pfizer stock — upbeat buying dominates ahead of Q4 2025 earnings

Traders Union
All News
Financial News
Pfizer jumps 3.17% to $26.70 today

Highlights

Pfizer traded at $26.70, above its MA-20, MA-50, and MA-200, confirming bullish momentum across all timeframes.
Momentum indicators, including a Buy signal on the MACD and an RSI of 56, support a positive short-term trend despite overbought signals in Stochastic RSI and CCI.
For the next five trading days, Pfizer is expected to consolidate between $26.15 and $26.24, with a high probability (>80%) of sideways-to-bullish continuation.

Investor disappointment grows as revenue forecasts lag and COVID sales weaken

On December 16, Pfizer issued a 2026 revenue forecast that disappointed investors. The company's third-quarter 2025 revenue came in at about $16.7 billion, reflecting an operational decline driven by lower sales of COVID-19 treatments Paxlovid and Comirnaty. Pfizer and BioNTech also completed an early-stage trial for a combined flu and COVID vaccine, and the company's Q4 2025 earnings report is scheduled for February 3, 2026.

Bullish momentum endures while technicals flag overbought conditions

Pfizer is supported by bullish signals from its short-, medium-, and long-term moving averages, with the price well above the MA-20 ($25.42), MA-50 ($25.42), and MA-200 ($24.53). Key technical levels include dynamic support at the Ichimoku Kijun ($25.57) and resistance close to the MA-50 ($25.42) as well as the round $27 mark. Momentum readings are constructive — MACD is on Buy, RSI stands at 56, and the Awesome Oscillator also confirms upward direction. Stochastic RSI and CCI are both in overbought territory, the ADX trend strength is neutral, and Bull/Bear Power points to continued buyer dominance intraday.

Sideways-to-bullish bias prevails amid low volatility and breakout risks

For the next five sessions, PFE is forecast to remain in a narrow volatility band between $26.15 and $26.24, just above the latest close. The likelihood of further upward price movement is very high (over 80%), while a pullback is less probable. A move above $26.24 could trigger additional gains toward $27, while a drop below $26.15 would test recent support, though overall signals continue to favor a sideways-to-bullish outlook.

Viktoras Karapetjanc, expert at Traders Union, notes that Pfizer is demonstrating strong technical momentum despite recent fundamental challenges. He believes that persistent investor confidence and robust support from all major moving averages suggest a high probability of continued gains. The analyst sees any pullbacks likely to be limited, with upside targets focused on resistance at $27. Macro and sentiment factors appear supportive for now, overshadowing recent revenue concerns. "Momentum and market sentiment are both favoring Pfizer — as long as $26.15 holds, I expect buyers to remain in control."

Last time, analysts noted that Pfizer Inc. is hovering just above key moving averages, reflecting short-term indecision but medium- and long-term support amid mixed momentum, neutral-to-positive RSI, a mild MACD bullish bias, and conflicting oscillator signals. Immediate support lies near $25.28 and the MA-50, with resistance at $26, suggesting price action may remain range-bound as volatility and technical drivers stay balanced.

Source of Data: PFE Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.